Sale of majority stake in Medix Biochemica

Avance advises Minerva Foundation, Folkhälsans forskningsstiftelse and Medicinska Understödsföreningen Liv och Hälsa in the sale of a majority stake in Finnish biotechnology company Medix Biochemica to DevCo Partners. Following the transaction, Minerva Foundation will continue as a significant shareholder in the company. Medix Biochemica is a leading manufacturer of bioreagents for the global IVD industry. In addition, it offers diagnostic tests specifically designed for the women’s health sector.